Xeris Pharmaceuticals Inc (NASDAQ:XERS)’s stock price shot up 7.2% during mid-day trading on Friday . The company traded as high as $11.75 and last traded at $11.59, 117,900 shares traded hands during trading. A decline of 45% from the average session volume of 213,337 shares. The stock had previously closed at $10.81.
A number of brokerages recently issued reports on XERS. Mizuho reissued a “buy” rating and set a $27.00 price target on shares of Xeris Pharmaceuticals in a research report on Thursday, July 25th. Royal Bank of Canada set a $18.00 price target on Xeris Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 7th.
The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.00 and a current ratio of 6.00. The stock has a 50-day moving average of $11.66 and a 200-day moving average of $10.88.
A number of large investors have recently modified their holdings of the stock. Northern Trust Corp grew its position in Xeris Pharmaceuticals by 1.5% during the fourth quarter. Northern Trust Corp now owns 74,423 shares of the company’s stock worth $1,265,000 after buying an additional 1,089 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Xeris Pharmaceuticals by 2.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 54,773 shares of the company’s stock valued at $627,000 after purchasing an additional 1,434 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Xeris Pharmaceuticals in the 2nd quarter valued at $26,000. Tower Research Capital LLC TRC acquired a new stake in shares of Xeris Pharmaceuticals in the 2nd quarter valued at $42,000. Finally, BNP Paribas Arbitrage SA acquired a new stake in shares of Xeris Pharmaceuticals in the 1st quarter valued at $43,000. 59.53% of the stock is currently owned by institutional investors and hedge funds.
About Xeris Pharmaceuticals (NASDAQ:XERS)
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Story: How do CD ladders protect against rising interest rates?
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.